Published in JACC Cardiovasc Imaging on May 01, 2013
CORonary MICrovascular Angina (CorMicA) (CorMicA) | NCT03193294
Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation (2014) 2.59
Coronary microvascular dysfunction: an update. Eur Heart J (2013) 1.28
Quantitation of myocardial blood flow and myocardial flow reserve with 99mTc-sestamibi dynamic SPECT/CT to enhance detection of coronary artery disease. Eur J Nucl Med Mol Imaging (2014) 0.92
PET tracers and techniques for measuring myocardial blood flow in patients with coronary artery disease. J Biomed Res (2013) 0.90
Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X. JACC Cardiovasc Imaging (2013) 0.86
Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2015) 0.80
Coronary microvascular dysfunction in women: an overview of diagnostic strategies. Expert Rev Cardiovasc Ther (2013) 0.78
Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. Circulation (2014) 0.78
Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests. Int J Cardiovasc Imaging (2017) 0.78
Epicardial adipose tissue thickness is increased in patients with cardiac syndrome X. Int J Clin Exp Med (2014) 0.77
Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nat Rev Cardiol (2015) 0.77
Current Diagnostic and Therapeutic Strategies in Microvascular Angina. Curr Emerg Hosp Med Rep (2015) 0.75
Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Circulation (2017) 0.75
CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. Int J Cardiol Heart Vasc (2017) 0.75
Evaluation of adiponectin and lipoprotein(a) levels in cardiac syndrome X. Herz (2015) 0.75
5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. Br J Pharmacol (2017) 0.75
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med (2003) 2.92
Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation (2002) 2.73
Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation (2014) 2.65
Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol (2007) 2.56
Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 tesla. J Am Coll Cardiol (2012) 2.38
High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ Res (2012) 2.26
High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol (2012) 2.24
Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol (2007) 2.22
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol (2004) 2.00
Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation (2003) 1.91
Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med (2010) 1.89
Stunning, hibernation, and assessment of myocardial viability. Circulation (2008) 1.83
Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J (2011) 1.82
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis (2008) 1.76
Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med (2005) 1.74
Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation (2003) 1.68
The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 1.66
Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol (2006) 1.65
Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis (2011) 1.63
Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography. Circ Cardiovasc Imaging (2009) 1.61
Systemic inhibition of nitric oxide synthase unmasks neural constraint of maximal myocardial blood flow in humans. Circulation (2004) 1.59
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J (2005) 1.58
Absolute quantification of myocardial blood flow with H(2)(15)O and 3-dimensional PET: an experimental validation. J Nucl Med (2002) 1.57
Cystatin C and cardiovascular risk. Clin Chem (2009) 1.57
Pharmacological treatment of chronic stable angina pectoris. Clin Med (2013) 1.51
Fear of dying and inflammation following acute coronary syndrome. Eur Heart J (2011) 1.50
Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis (2006) 1.49
Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Eur Heart J (2008) 1.48
Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol (2007) 1.47
New universal definition of myocardial infarction applicable after complex percutaneous coronary interventions? JACC Cardiovasc Interv (2010) 1.46
Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation (2004) 1.45
Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol (2013) 1.44
Obesity, inflammation and brachial artery flow-mediated dilatation: therapeutic targets in patients with microvascular angina (cardiac syndrome X). Cardiovasc Drugs Ther (2012) 1.43
Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res (2007) 1.43
Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res (2005) 1.40
Comparison of myocardial blood flow and coronary flow reserve during dobutamine and adenosine stress: Implications for pharmacologic stress testing in coronary artery disease. J Nucl Cardiol (2006) 1.39
Patent foramen ovale closure and brain ischaemic lesions. Heart (2013) 1.39
Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation (2002) 1.36
C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J (2004) 1.35
Myocardial blood flow in patients with hibernating myocardium. Cardiovasc Res (2003) 1.29
Coronary microvascular dysfunction: an update. Eur Heart J (2013) 1.28
Program of cell survival underlying human and experimental hibernating myocardium. Circ Res (2004) 1.27
Coronary microvascular resistance: methods for its quantification in humans. Basic Res Cardiol (2009) 1.26
Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J (2009) 1.26
C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol (2003) 1.24
Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J (2003) 1.23
Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging (2010) 1.19
Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J (2012) 1.18
Neurocognitive function and cerebral emboli: randomized study of on-pump versus off-pump coronary artery bypass surgery. Ann Thorac Surg (2007) 1.18
Microvascular dysfunction in cardiac syndrome X: the role of inflammation. CMAJ (2006) 1.15
Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation (2004) 1.14
Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol (2006) 1.13
Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J (2009) 1.12
Respiratory gating of cardiac PET data in list-mode acquisition. Eur J Nucl Med Mol Imaging (2006) 1.10
Evaluation of the microcirculation in hypertension and cardiovascular disease. Eur Heart J (2007) 1.09
Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J (2012) 1.08
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 1.07
Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J (2012) 1.07
Can silent brain lesions be a target to guide anticoagulation treatment in patients with low-risk atrial fibrillation to reduce cognitive impairment? J Am Coll Cardiol (2014) 1.06
Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis (2011) 1.05
Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J Am Coll Cardiol (2010) 1.05
The clinical value of myocardial blood flow measurement. J Nucl Med (2009) 1.04
Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations. Atherosclerosis (2009) 1.04
Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis (2004) 1.04
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol (2011) 1.03
Pulse pressure and progression of chronic kidney disease. J Nephrol (2010) 1.03
Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med (2008) 1.02
Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol (2005) 1.02
Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J Am Coll Cardiol (2006) 1.01
Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes (2002) 1.00
The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol (2011) 0.99
A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings. Cardiovasc Res (2008) 0.98
Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J (2005) 0.97
Epidemiology of the diabetic heart. Coron Artery Dis (2005) 0.97
Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol (2003) 0.97
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation (2004) 0.96
Myocardial infarction in the elderly. Aging Dis (2010) 0.96
Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis (2006) 0.96
CD4+ CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res (2008) 0.95
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 0.95
Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation (2004) 0.93
[Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC]. Kardiol Pol (2005) 0.93
Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem (2004) 0.93
Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol (2005) 0.93
Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J (2010) 0.91
Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol (2002) 0.91
Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis (2008) 0.91
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med (2008) 0.91